Sleep Disorder Market Share, Size, Trends, & Industry Analysis Report 2026
The sleep disorder market size is anticipated to reach over USD 1.31 billion by 2017. In 2017, the sleep apnea devices dominated the global market, in terms of revenue. Asia-Pacific is expected to be the Fastest growing contributor to the global market revenue in 2017.
Sleep is complex neurological state that helps in restoring energy level in the body. Alterations in the quality and pattern if sleep may cause sleep disorder. Sleep disorder is defined as a sleep problem, which is characterized by snoring, insomnia, depression, and sleep apnea. Recently, in a study it is found that the approximately more than 75% of Americans from the age of 25 to 59 suffer from sleep disorder in the U.S. Sleep disorder is basically characterize by the difficulty in falling asleep, daytime fatigue, lack of concentration, anxiety, and depression.
Download Sample Report Pages for Better understanding @ https://www.4arcresearch.com/request-sample-23602
The sleep disorder market is primarily driven by the increasing number individual population suffering from various mental disorders, and rising awareness for the treatment of sleep disorders in the coming years. Furthermore, the changing life style of the people, and rising preference to the sedentary life style to also support the market growth in the coming years. Additionally, changing working culture, increasing geriatric population, and lack of quality sleep to also boost the market growth during the forecast period.
On the other side, increasing morbidity due to sleep disorder has increased the healthcare cost, and related side effects of the drugs, and increasing patent expiries that are used in treating sleep disorders which would impede the market growth during the forecast period. The treatment for include medication, better sleeping habits, and devices. Medicines such as, Hetlioz (tasimelteon) by Vanda Pharmaceuticals, Intermezzo (zolpidem tartrate sublingual tablet) by Transcept Pharmaceuticals, and Silenor (doxepin) by Somaxon Pharma are some of the FDA approved drugs that are observed to be beneficial during the treatment of sleep disorders.
The market for sleep disorder in North America generated the highest revenue in 2017, and is expected to be the leading region globally during the forecast period. High number of patient population suffering the sleeping disorders is the primary factor accountable for the highest market growth. According to the US Department of Health and Human Services reports, approximately 20% Americans are suffering from sleep disorder. Thus, increasing demand for early treatments along with increasing patient pool, and growing patient awareness for proper diagnosis methods are factors boosting the growth in North America.
Asia Pacific is estimated to be the fastest growing region in terms of revenue. Growing awareness about sleep disorders and developing healthcare infrastructure are some of the factors that are projected to generate lucrative opportunities for the market in APAC.
The major key players operating in the Sleep Disorder industry include GlaxoSmithKline plc, Becton Dickson and Company, Cardinal Health, Natus Medical Incorporated Takeda Pharmaceutical Company Limited, Koninklijke Philips N.V., and Teva Pharmaceutical Industries Ltd. These companies launch new products and collaborate with other market leaders to innovate and launch new products to meet the increasing needs and requirements of consumers.
Enquire before buy or customization in Report: https://www.4arcresearch.com/request-for-customization-23602
About 4Arc Research:
4Arc Research, Inc., is a pioneering market research and consulting firm which is dedicated in providing reports on syndicated market research and customised market research. We leave no stone unturned while following smart study of the public demands, capabilities and the continuous growth of the working industry, interactive environment between the client-server, dynamic reporting, and high data protection services.